Assessment of IL-17 in multiple sclerosis and its relationship with disease severity in Egypt
The Egyptian journal of Immunology · 2025
DOI: 10.55133/eji.320402 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Egyptian journal of Immunology, 2025. Verfasst von Mona Salama und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pathology, Faculty of Medicine, Port Said University, Port Said, Egypt. Hauptthemen laut MEDLINE: Interleukin-17, Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting.
Abstract (Originalsprache)
Central nervous system (CNS) demyelination and neurodegeneration are hallmarks of multiple sclerosis (MS). The pathophysiology of MS is related to the inflammatory cytokine interleukin-17 (IL-17), and there may be an association between IL-17 levels and disease severity. In order to find a non-invasive biomarker for disease progression, serum IL-17 levels in MS patients were measured in comparison to a matched control group. Additionally, the relationship between serum IL-17 levels and MS activity was examined. This case-control study included 31 MS patients who were diagnosed using the 2017 updated McDonald's criteria and a control group consisted of 20 apparently healthy individuals, matched for both age and sex. Serum samples were collected and analyzed for IL-17 concentrations using ELISA commercial kits. Clinical evaluations included demographic data, medical history, and an assessment of disease severity using the Expanded Disability Status Scale (EDSS). The study assessed serum levels of IL-17, and found significantly higher levels in MS patients (38.79± 37.36) in comparison to controls (1.47± 0.49). Levels of IL-17 were increased in secondary progressive MS patients than in relapsing-remitting MS patients, but did not reach statistical significance. No significant associations were identified between IL-17 levels and the duration of the MS disease or the frequency of relapses. In conclusion, the study pointed to increased IL-17 levels as a potential MS biomarker.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pathology, Faculty of Medicine, Port Said University, Port Said, Egypt.
- Department of Medical Microbiology and Immunology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
- Department of Clinical Pathology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
- Department of Neurology, Faculty of Medicine, Suez Canal University, Ismailia, Egypt.
- Department of Histology and Cell Biology, Faculty of Medicine, Menoufia University, Menoufia, Egypt.
- Department of Histology, General Medicine Practice Program, Batterjee Medical College, Aseer 61961, Saudi Arabia.
Zitieren
APA
Salama, M., Mareia, Y., Attia, F., Anani, M., El-Samahy, M., Mohamed, S., Alqassimi, S., Albeltagy, E. S., Roshdey, E., Ahmed, S., & Greash, M. (2025). Assessment of IL-17 in multiple sclerosis and its relationship with disease severity in Egypt. The Egyptian journal of Immunology. https://doi.org/10.55133/eji.320402
Vancouver
Salama M, Mareia Y, Attia F, Anani M, El-Samahy M, Mohamed S, et al. Assessment of IL-17 in multiple sclerosis and its relationship with disease severity in Egypt. The Egyptian journal of Immunology. 2025. doi:10.55133/eji.320402
BibTeX
@article{Salama2025,
author = {Salama, Mona and Mareia, Yara and Attia, Fadia and Anani, Maha and El-Samahy, Mohamed and Mohamed, Shaimaa and Alqassimi, Sameer and Albeltagy, Eman S and Roshdey, Eman and Ahmed, Sahar and Greash, Mohamed},
title = {Assessment of IL-17 in multiple sclerosis and its relationship with disease severity in Egypt},
journal = {The Egyptian journal of Immunology},
year = {2025},
doi = {10.55133/eji.320402}
}
EUVIMED